After Needham and H.C. Wainwright gave Aerie Pharma (NASDAQ: AERI) a Buy rating last month, the company received another Buy, this time from Mizuho Securities. Analyst Difei Yang maintained a Buy rating on Aerie Pharma today and set a price target of $29.00. The company’s shares closed last Thursday at $16.01.
According to TipRanks.com, Yang has 0 stars on 0-5 stars ranking scale with an average return of -6.6% and a 36.0% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals, Sarepta Therapeutics, and Revance Therapeutics.
Aerie Pharma has an analyst consensus of Strong Buy, with a price target consensus of $29.00, representing a 79.5% upside. In a report issued on May 7, Piper Sandler also maintained a Buy rating on the stock with a $35.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $40.25 and a one-year low of $10.80. Currently, Aerie Pharma has an average volume of 1.03M.
Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AERI in relation to earlier this year. Earlier this month, Murray Goldberg, a Director at AERI bought 28,000 shares for a total of $88,200.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.
Read More on AERI: